Boai NKY Medical Holdings Croissance future

Future contrôle des critères 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Boai NKY Medical Holdings.

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Chemicals croissance des bénéfices	38.3%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	None
Dernière mise à jour	n/a

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

We Think That There Are More Issues For Boai NKY Medical Holdings (SZSE:300109) Than Just Sluggish Earnings

Oct 31

Market Might Still Lack Some Conviction On Boai NKY Medical Holdings Ltd. (SZSE:300109) Even After 40% Share Price Boost

Oct 08

Boai NKY Medical Holdings Ltd. (SZSE:300109) Doing What It Can To Lift Shares

Aug 23

Does Boai NKY Medical Holdings (SZSE:300109) Have A Healthy Balance Sheet?

Jul 25

Boai NKY Medical Holdings (SZSE:300109) Is Paying Out A Larger Dividend Than Last Year

Jun 04

We Like These Underlying Return On Capital Trends At Boai NKY Medical Holdings (SZSE:300109)

May 27

Should You Be Adding Boai NKY Medical Holdings (SZSE:300109) To Your Watchlist Today?

Apr 03

Boai NKY Medical Holdings Ltd. (SZSE:300109) Stock Rockets 39% But Many Are Still Ignoring The Company

Mar 04

Dans cette section, nous présentons généralement des projections de croissance du chiffre d'affaires et des bénéfices basées sur les estimations consensuelles d'analystes professionnels afin d'aider les investisseurs à comprendre la capacité de l'entreprise à générer des bénéfices. Mais comme Boai NKY Medical Holdings n'a pas fourni suffisamment de données passées et n'a pas de prévisions d'analystes, ses bénéfices futurs ne peuvent pas être calculés de manière fiable en extrapolant les données passées ou en utilisant les prévisions des analystes.

Il s'agit d'une situation assez rare car 97% des entreprises couvertes par SimplyWall St disposent de données financières passées.

Prévisions de croissance des bénéfices et des revenus

SZSE:300109 - Estimations futures des analystes et données financières antérieures (CNY Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
9/30/2024	1,488	399	125	427	N/A
6/30/2024	1,539	444	150	468	N/A
3/31/2024	1,615	494	166	513	N/A
12/31/2023	1,583	493	110	488	N/A
9/30/2023	1,566	419	88	505	N/A
6/30/2023	1,586	408	83	453	N/A
3/31/2023	1,538	379	189	531	N/A
1/1/2023	1,486	291	-14	252	N/A
9/30/2022	1,481	385	-198	86	N/A
6/30/2022	1,362	270	-319	-12	N/A
3/31/2022	1,246	177	-397	-140	N/A
1/1/2022	1,220	207	-185	43	N/A
9/30/2021	1,158	68	29	141	N/A
6/30/2021	1,070	77	196	266	N/A
3/31/2021	1,043	95	177	277	N/A
12/31/2020	979	45	168	267	N/A
9/30/2020	950	96	154	269	N/A
6/30/2020	973	113	47	173	N/A
3/31/2020	987	106	-1	107	N/A
12/31/2019	924	123	-63	80	N/A
9/30/2019	879	113	-110	28	N/A
6/30/2019	785	96	-146	-13	N/A
3/31/2019	716	94	-74	60	N/A
12/31/2018	698	90	-76	49	N/A
9/30/2018	621	98	-85	13	N/A
6/30/2018	567	95	N/A	5	N/A
3/31/2018	522	93	N/A	-3	N/A
12/31/2017	489	93	N/A	47	N/A
9/30/2017	455	91	N/A	94	N/A
6/30/2017	429	89	N/A	118	N/A
3/31/2017	414	84	N/A	110	N/A
12/31/2016	401	80	N/A	114	N/A
9/30/2016	381	82	N/A	99	N/A
6/30/2016	366	74	N/A	83	N/A
3/31/2016	320	64	N/A	75	N/A
12/31/2015	291	57	N/A	64	N/A
9/30/2015	263	46	N/A	46	N/A
6/30/2015	255	42	N/A	46	N/A
3/31/2015	256	38	N/A	49	N/A
12/31/2014	253	30	N/A	47	N/A
9/30/2014	243	27	N/A	26	N/A
6/30/2014	223	23	N/A	34	N/A
3/31/2014	217	21	N/A	26	N/A
12/31/2013	209	20	N/A	23	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Insufficient data to determine if 300109's forecast earnings growth is above the savings rate (2.9%).

Bénéfices vs marché: Insufficient data to determine if 300109's earnings are forecast to grow faster than the CN market

Croissance élevée des bénéfices: Insufficient data to determine if 300109's earnings are expected to grow significantly over the next 3 years.

Chiffre d'affaires vs marché: Insufficient data to determine if 300109's revenue is forecast to grow faster than the CN market.

Croissance élevée des revenus: Insufficient data to determine if 300109's revenue is forecast to grow faster than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Insufficient data to determine if 300109's Return on Equity is forecast to be high in 3 years time

Boai NKY Medical Holdings Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

We Think That There Are More Issues For Boai NKY Medical Holdings (SZSE:300109) Than Just Sluggish Earnings

New minor risk - Shareholder dilution

Third quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.30 in 3Q 2023)

Investor sentiment deteriorates as stock falls 20%

Market Might Still Lack Some Conviction On Boai NKY Medical Holdings Ltd. (SZSE:300109) Even After 40% Share Price Boost

Boai NKY Medical Holdings Ltd. to Report Q3, 2024 Results on Oct 23, 2024

Investor sentiment improves as stock rises 22%

Now 26% overvalued

Second quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.29 in 2Q 2023)

Boai NKY Medical Holdings Ltd. (SZSE:300109) Doing What It Can To Lift Shares

Does Boai NKY Medical Holdings (SZSE:300109) Have A Healthy Balance Sheet?

Boai NKY Medical Holdings Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Boai NKY Medical Holdings (SZSE:300109) Is Paying Out A Larger Dividend Than Last Year

Dividend increased to CN¥1.00

Boai NKY Medical Holdings Ltd. Announces Implementation of Final A Share Cash Dividend for 2023, Payable on 07 June 2024

We Like These Underlying Return On Capital Trends At Boai NKY Medical Holdings (SZSE:300109)

Boai NKY Medical Holdings Ltd. Approves Cash Dividend for the Year 2023

Boai NKY Medical Holdings Ltd., Annual General Meeting, May 23, 2024

First quarter 2024 earnings released: EPS: CN¥0.38 (vs CN¥0.39 in 1Q 2023)

Boai NKY Medical Holdings Ltd. Proposes Final Cash Dividend for 2023

Should You Be Adding Boai NKY Medical Holdings (SZSE:300109) To Your Watchlist Today?

Now 23% overvalued after recent price rise

Boai NKY Medical Holdings Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Boai NKY Medical Holdings Ltd. (SZSE:300109) Stock Rockets 39% But Many Are Still Ignoring The Company

Full year 2023 earnings released: EPS: CN¥1.63 (vs CN¥0.88 in FY 2022)

Boai NKY Medical Holdings Ltd. announced that it expects to receive CNY 623 million in funding

Boai NKY Medical Holdings Ltd. announced that it expects to receive CNY 623 million in funding

Investor sentiment deteriorates as stock falls 20%

Boai NKY Medical Holdings Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Third quarter 2023 earnings released: EPS: CN¥0.45 (vs CN¥0.42 in 3Q 2022)

Boai NKY Medical Holdings Ltd. to Report Q3, 2023 Results on Oct 25, 2023

Second quarter 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.34 in 2Q 2022)

Boai NKY Medical Holdings Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on May 30, 2023

Boai NKY Medical Holdings Ltd. Approves Cash Dividend for 2022

First quarter 2023 earnings released: EPS: CN¥0.39 (vs CN¥0.10 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.96 (vs CN¥0.91 in FY 2021)

Investor sentiment deteriorated over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.046 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Gryningskust Holding AB acquired additional 14.0 % minority stake in NeoDynamics AB (publ) (OM:NEOD).

Boai NKY Medical Holdings Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on 30 May 2022

Boai NKY Medical Holdings Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on 30 May 2022

Boai Nky Medical Holdings Ltd. Approves Cash Dividend

Boai NKY Medical Holdings Ltd. Proposes Final Cash Dividend for the Year 2021

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS and revenues miss analyst expectations

Boai NKY Medical Holdings Ltd. (SZSE:300109) commences a Equity Buyback Plan under the authorization approved on December 21, 2021.

Third quarter 2021 earnings released: EPS CN¥0.046 (vs CN¥0.08 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.067 (vs CN¥0.12 in 2Q 2020)

Abcam plc (AIM:ABC) entered into a definitive agreement to acquire BioVision, Inc. from Boai NKY Medical Holdings Ltd. (SZSE:300109) for approximately $340 million.

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Shanghai Haitong Securities Assets Management Co.,Ltd. completed the acquisition of 3% stake in Boai NKY Medical Holdings Ltd. (SZSE:300109) from Wang Donghu.

Boai Nky Medical Holdings Ltd. Approves Final Cash Dividend for 2020

Boai NKY Medical Holdings Ltd. Proposes Final Cash Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.04 in 1Q 2020)

Investor sentiment deteriorated over the past week

New 90-day low: CN¥11.20

New 90-day low: CN¥11.89

Ningbo Tianlong Electronics Co., Ltd. (SHSE:603266) entered into a equity transfer agreement to acquire 4.1818% stake in Wuhan First Bioscience Inc. from Boai NKY Medical Holdings Ltd. (SZSE:300109) for CNY 14 million.

New 90-day low: CN¥13.80

New 90-day low: CN¥15.06

New 90-day low: CN¥16.55

Third quarter earnings released

Market bids up stock over the past week

New 90-day high: CN¥19.40

New 90-day high: CN¥19.24

Fang Huasheng and Ren Dalong acquired 18.99% stake in Boai NKY Pharmaceuticals Ltd. (SZSE:300109).

New 90-day high - CN¥18.63

Earnings released

Boai NKY Medical Holdings Ltd. to Report First Half, 2020 Results on Aug 27, 2020